{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:39:31Z","timestamp":1793093971055,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017027","name":"Julius Clinical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132946"],"award-info":[{"award-number":["101132946"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejim.2026.107191","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:03:04Z","timestamp":1791518584000},"page":"107191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Receptivity and susceptibility to care models for Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in Europe: a mixed-methods, landscaping study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9944-422X","authenticated-orcid":false,"given":"Leonard D.","family":"Broekman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0440-2063","authenticated-orcid":false,"given":"Kirsi M.A.","family":"van Eekhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1291-1343","authenticated-orcid":false,"given":"Sophie","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.M.","family":"Konings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Carvalhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-7491","authenticated-orcid":false,"given":"Ioanna P.","family":"Kalafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-0068","authenticated-orcid":false,"given":"Luca","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Castro","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8780-476X","authenticated-orcid":false,"given":"Jean W.","family":"Muris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Mendive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine J.M.W.","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Vonghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven M.","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten E.","family":"Tushuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G.","family":"Holleboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar H.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"do Mar d\u2019Orey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cortez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Dedoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Mentsiou-Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Lara-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Maya-Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Massoels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107191_bib0001","article-title":"Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries","author":"Younossi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107191_bib0003","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0004","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/joim.20103","article-title":"Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care","volume":"298","author":"Balkhed","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2026.107191_bib0005","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2026.107191_bib0006","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the american diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2026.107191_bib0007","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107191_bib0008","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/diseases12080180","article-title":"Practice recommendations for the management of MASLD in primary care: consensus results","volume":"12","author":"Lionis","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.ejim.2026.107191_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101789","article-title":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","volume":"30","author":"Younossi","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0011","article-title":"Advanced MASLD Fibrosis: low number-needed-to-screen in multiple lines of care [Abstract]. annual dutch diabetes research meeting","author":"Driessen","year":"2025","journal-title":"Wageningen"},{"key":"10.1016\/j.ejim.2026.107191_bib0012","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ueg2.12445","article-title":"A global survey of health care workers' awareness of non-alcoholic fatty liver disease: the AwareNASH survey. United","volume":"11","author":"Driessen","year":"2023","journal-title":"Eur Gastroenterol J"},{"key":"10.1016\/j.ejim.2026.107191_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16224","article-title":"A European survey to identify challenges in the management of metabolic dysfunction-associated steatotic liver disease","volume":"45","author":"Castera","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2026.107191_bib0014","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0015","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Anstee","year":"2022","journal-title":"Jhep Rep"},{"key":"10.1016\/j.ejim.2026.107191_bib0016","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jceh.2023.01.016","article-title":"Comparison of guidelines for the screening, diagnosis, and noninvasive assessment of nonalcoholic fatty liver disease","volume":"13","author":"Chow","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0017","first-page":"10","article-title":"The breadth of primary care: a systematic literature review of its core dimensions","author":"Kringos","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ejim.2026.107191_bib0018","first-page":"2040","article-title":"A comparative analysis of qualitative and mixed methods research: strengths, limitations, and practical applications","volume":"25","author":"Gamage","year":"2025","journal-title":"WJARAI"},{"key":"10.1016\/j.ejim.2026.107191_bib0019","unstructured":"Hong Q.N., Pluye P., F\u00e0bregues S., Bartlett G., Boardman F., Cargo M., et al. Mixed Methods Appraisal Tool (MMAT), version 2018. Registration of Copyright (#1148552), Canadian Intellectual Property Office, Industry Canada."},{"key":"10.1016\/j.ejim.2026.107191_bib0020","first-page":"15","article-title":"Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study","author":"de Jong","year":"2025","journal-title":"Bmj Open"},{"key":"10.1016\/j.ejim.2026.107191_bib0021","first-page":"45","article-title":"A European survey to identify challenges in the management of metabolic dysfunction-associated steatotic liver disease","author":"Castera","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2026.107191_bib0022","first-page":"791","article-title":"Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa countries: insights into guidelines, infrastructure, and referral systems","volume":"13","author":"El-Kassas","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0024","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/imj.15422","article-title":"Towards collaborative management of non-alcoholic fatty liver disease: a 'real-world' pathway for fibrosis risk assessment in primary care","volume":"52","author":"Hayward","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.ejim.2026.107191_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-06140-w","article-title":"The effectiveness of different patient referral systems to shorten waiting times for elective surgeries: systematic review","volume":"21","author":"Rathnayake","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ejim.2026.107191_bib0026","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of D, European Association for the Study of O, European Association for the Study of the L. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0027","first-page":"16","article-title":"Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances","author":"Wu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejim.2026.107191_bib0028","article-title":"Steatotic liver disease trajectory: a holistic EASL guidance on the multidisciplinary approach to screening and patient management","volume":"8","author":"Brouwer","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ejim.2026.107191_bib0029","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s43856-025-00871-1","article-title":"The importance of patient engagement in the multimodal treatment of MASLD","volume":"5","author":"Boeckmans","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.ejim.2026.107191_bib0030","first-page":"154","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease prevalence","volume":"70","author":"Miller","year":"2025","journal-title":"Diagn Treat Outcomes Narrat Rev Dig Dis Sci"},{"key":"10.1016\/j.ejim.2026.107191_bib0031","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.14309\/ajg.0000000000003421","article-title":"Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis","volume":"120","author":"Abu-Rumaileh","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2026.107191_bib0033","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2026.107191_bib0034","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s44360-026-00066-5","article-title":"How to integrate steatotic liver disease screening and treatment into clinical care","volume":"1","author":"Driessen","year":"2026","journal-title":"Nat Health"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:46:49Z","timestamp":1791575209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526004966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S0953620526004966"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107191","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Receptivity and susceptibility to care models for Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in Europe: a mixed-methods, landscaping study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107191"}}